BoneFDA Approved

Abaloparatide (Tymlos)

Subcutaneous injection (daily)

Overview

A synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34) that selectively activates the RG conformation of the PTH1 receptor. This receptor selectivity produces a more transient signaling response compared to teriparatide, favoring anabolic bone formation with less stimulation of bone resorption and calcium mobilization.

Mechanism of Action

Abaloparatide increases bone mineral density at both cortical and trabecular sites..

Research Summary & Key Findings

FDA-approved in 2017 for osteoporosis in postmenopausal women at high fracture risk. ACTIVE trial demonstrated 86% reduction in vertebral fractures and 43% reduction in nonvertebral fractures vs. placebo. Lower incidence of hypercalcemia compared to teriparatide (3.4% vs. 6.4%). ACTIVExtend study showed continued fracture protection when transitioning to alendronate.

Clinical Status

FDA Approved

Abaloparatide (Tymlos) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.

Administration Routes

Subcutaneous injection (daily)

Related Peptides in Bone

Find a Provider

Find a verified provider who offers Abaloparatide (Tymlos) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Abaloparatide (Tymlos).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.